PTEN (N-term) Rabbit Polyclonal Antibody

Specifications

Product Data
Applications	IF, IHC, WB
Recommend Dilution	Western blotting: 1/1000. Immunofluorescence: 1/10-1/50. Immunohistochemistry on Paraffin Sections: 1/50-1/100.
Reactivity	Human
Host	Rabbit
Clonality	Polyclonal
Immunogen	KLH conjugated synthetic peptide between 69-104 amino acids from the N-terminal region of Human PTEN.
Specificity	This antibody recognizes Human PTEN at N-term. Other species not tested.
Formulation	PBS State: Purified State: Liquid purified Ig fraction Preservative: 0.09% (W/V) Sodium Azide
Concentration	lot specific
Purification	Protein G column, eluted with high and low pH buffers and neutralized immediately, followed by dialysis against PBS
Conjugation	Unconjugated
Storage Condition	Store undiluted at 2-8°C for one month or (in aliquots) at -20°C for longer. Avoid repeated freezing and thawing.
Predicted Protein Size	47166 Da
Gene Name	phosphatase and tensin homolog
Database Link	Entrez Gene 5728 Human UniProt ID P60484
Background	PTEN, (phosphatase and tensin homolog deleted on chromosome 10), also known as MMAC1 (mutated in multiple advanced cancers 1), is a tumor suppressor implicated in a large number of human tumors. The PTEN phosphatase incorporates the catalytic motif (HCXXGXXRS/T) that is a signature of the protein tyrosine phosphatase family. Recombinant human PTEN is a dual phosphatase with ability to dephosphorylate both tyrosine and serine/threonine residues. PTEN functions primarily as a lipid phosphatase to regulate signal transduction pathways, with a primary target identified as phosphatidylinositol 3,4,5 trisphosphate. In addition, PTEN presents weak tyrosine phosphatase activity, which may downregulate signaling pathways involving focal adhesion kinase or Shc. PTEN negatively regulates activation of the serine/threonine kinase Akt/PKB by blocking its phosphorylation, thereby inhibiting the PI 3 kinase Akt signaling pathway, which is important for cell survival. In vivo, the majority of PTEN missense mutations detected in tumor specimens target the phosphatase domain and cause a loss in PTEN phosphatase activity. Mutations in PTEN are associated with several common cancers including prostate, brain and breast cancer, and with Cowden's disease, an autosomal dominant disorder conferring susceptibility to benign and malignant tumors. Germline mutations of PTEN are also linked Lhermitte-Duclos disease and Bannayan-Zonana syndrome. Mutations of PTEN occur in 60 to 80% of prostate cancers. PTEN is also essential for embryonic development.
Synonyms	MMAC1, TEP1
Reference Data

*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.